The ENCIRCLE Trial
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Atlanta, Austin, Baltimore, Baton Rouge, Boston, Buffalo, Charlotte, Cincinnati, Cleveland, Columbus, Detroit, Gainesville, Glenview, Houston, Huntsville, Jacksonville, Kansas City, La Jolla, Lebanon, Los Angeles, Loveland, Mechanicsburg, Murray, Naples, Nashville, New Brunswick, New York, Norfolk, Oklahoma City, Phoenix, Roanoke, Rochester, Saint Cloud, San Francisco, Sarasota, Seattle, Tulsa, and Wichita, United StatesSee the 44 sitesAlso in 5 other countries, 10 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 786 people enrolled
- Started
- 12 Nov 2020
- Expected to end
- 10 Oct 2031
- Type of study
- Interventional, 3 groups
- Treatments tested
- SAPIEN M3 valve and dock
- Record updated
- 6 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- 18 years of age or older
- MR ≥ 3+
- NYHA functional class ≥ II
- Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations
- Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment
- The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent
Who cannot take part
- Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure
- Renal insufficiency or receiving renal replacement therapy
- Planned surgery within the next 12 months
- Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure
- Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
- Participating in another investigational drug or device study that has not reached its primary endpoint
- Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve
- History of heart transplant
- Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
- Myocardial infarction within 30 days of the procedure
- Clinically significant untreated coronary artery disease requiring revascularization
- Stroke or transient ischemic attack within 90 days of the procedure
- Irreversible, severe pulmonary hypertension
- Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic outpatient oral steroid use
- Liver disease
- Active infection requiring current antibiotic therapy
- Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states
- Estimated life expectancy <12 months due to non-cardiac conditions
- Left ventricular ejection fraction <25%
- Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve
- Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation
- Severe right ventricular dysfunction
- Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months
- Active bacterial endocarditis within 180 days of the procedure
- Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
- Refusal of blood products
- Female who is pregnant or lactating
- Subject considered to be part of a vulnerable population
Where in United States
Also in 5 other countries, 10 sites
- Emory UniversityAtlanta, United States
- Piedmont HealthcareAtlanta, United States
- Austin HeartAustin, United States
- MedStar Union Memorial HospitalBaltimore, United States
- Our Lady of the Lake Regional Medical CenterBaton Rouge, United States
- Massachusetts General HospitalBoston, United States
- University of BuffaloBuffalo, United States
- Novant Health and Vascular InstituteCharlotte, United States
- The Christ HospitalCincinnati, United States
- Cleveland Clinic FoundationCleveland, United States
- Mount Carmel East HospitalColumbus, United States
- Henry FordDetroit, United States
- Cardiac & Vascular Institute FoundationGainesville, United States
- Northshore University Health SystemGlenview, United States
- HCA Houston Healthcare Medical (SCRI)Houston, United States
- UT Memorial HermannHouston, United States
- Heart Center HospitalHuntsville, United States
- Ascension St. Vincent's HospitalJacksonville, United States
- Saint Luke's Kansas CityKansas City, United States
- University of KansasKansas City, United States
- Scripps HealthLa Jolla, United States
- Dartmouth Hitchcock Medical CenterLebanon, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- Good Samaritan HospitalLos Angeles, United States
- Kaiser Sunset LALos Angeles, United States
- UC Health Northern Colorado (Medical Center of the Rockies)Loveland, United States
- UPMC Heart and Vascular InstituteMechanicsburg, United States
- Intermountain Medical CenterMurray, United States
- Naples Community HospitalNaples, United States
- Saint Thomas HealthNashville, United States
- Robert Wood Johnson University HospitalNew Brunswick, United States
- Weill Cornell MedicineNew York, United States
- Sentara NorfolkNorfolk, United States
- Oklahoma Heart HospitalOklahoma City, United States
- Banner University Medical CenterPhoenix, United States
- Saint Josephs Hospital Medical Center Dignity HealthPhoenix, United States
- Carilion Roanoke Memorial HospitalRoanoke, United States
- Mayo ClinicRochester, United States
- CentraCareSaint Cloud, United States
- California Pacific Medical CenterSan Francisco, United States
- Sarasota Memorial HospitalSarasota, United States
- University of Washington-SeattleSeattle, United States
- Oklahoma Heart InstituteTulsa, United States
- Cardiovascular Research Institute of Kansas (CRIOK)Wichita, United States
About the trial
What the trial wants to find out
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.
Read full original descriptionShow less
Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
The 3 groups in the trial
- TMVR - Main CohortTreatment being tested
Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).
Treatment: SAPIEN M3 valve and dock
- TMVR - Failed TEER RegistryTreatment being tested
Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.
Treatment: SAPIEN M3 valve and dock
- TMVR - MAC RegistryTreatment being tested
Subjects with mitral annular calcification (MAC) will have TMVR.
Treatment: SAPIEN M3 valve and dock
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access
- Publications
- Percutaneous Transcatheter Mitral Valve Replacement for Symptomatic Mitral Regurgitation: 2-Year Outcomes From the ENCIRCLE Trial.Journal of the American College of Cardiology, 2026
- Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.Lancet (London, England), 2025
- Record updated
- 6 October 2026